Stem Cell Therapy for Sjögren's Syndrome

What This Article Covers

This article explains what mesenchymal stem cell (MSC) therapy for Sjögren's syndrome is, what current clinical trial evidence does and doesn't show, and who might realistically consider it. In short: several small trials show encouraging improvements in dry eye and gland function, but no stem cell therapy is FDA-approved for Sjögren's syndrome, and the evidence remains early-stage.

Sjögren's syndrome is an autoimmune condition in which immune cells attack the glands that produce tears and saliva, causing chronic dry eyes and dry mouth, fatigue, joint pain, and sometimes damage to other organs. Standard treatments — artificial tears, saliva stimulants, immunosuppressive drugs — manage symptoms but don't reverse gland damage or retrain the immune system. That gap is why stem cell therapy, which aims to calm the autoimmune attack rather than just mask symptoms, has drawn interest from patients and researchers alike.

How It's Thought to Work

Mesenchymal stem cells (MSCs) are adult stem cells typically sourced from fat tissue, umbilical cord tissue, or bone marrow. Rather than regrowing gland tissue directly, the leading theory is immunomodulation: MSCs release signals that appear to quiet the overactive T cells and B cells believed to drive gland destruction in Sjögren's. Lab and animal studies support this mechanism, showing MSCs can shift the immune environment toward a more regulatory, less destructive state.

Delivery varies by study. Some trials inject MSCs directly into the lacrimal or salivary glands to act locally; others infuse them intravenously to calm autoimmune activity body-wide.

What the Evidence Shows

The good news first: several controlled human trials report real, measurable improvements. A randomized trial in The Ocular Surface tested a single lacrimal-gland injection of allogeneic adipose-derived stem cells in Sjögren's patients with severe dry eye. The stem cell group showed a significant reduction in dry eye symptom scores and longer tear film stability versus controls, with benefits still detectable at 12 months.

A 2023 randomized, placebo-controlled trial in Scientific Reports injected adipose-derived stem cells into the salivary glands of primary Sjögren's patients. The treated group showed significantly improved salivary and tear gland secretion at three months and better disease-activity scores than placebo, with only minimal adverse effects reported.

Zooming out, a 2026 meta-analysis in Frontiers in Immunology pooled 5 trials covering 114 patients and found statistically significant improvements in dry eye measures after stem cell therapy — including a Schirmer test (tear production) improvement of 3.87 mm and a NIKBUT (tear film stability) increase of 3.26 points versus baseline.

On the systemic side, earlier work by Chinese rheumatology researchers (Sun and colleagues, published in Blood) tested intravenous umbilical cord MSC infusions in Sjögren's patients unresponsive to standard treatment, reporting increased salivary flow and reduced autoimmune antibody levels within a month, with no serious side effects. Related lab research has shown umbilical cord MSCs can suppress overactive immune cells drawn from Sjögren's patients' blood, supporting the proposed mechanism.

Now the caveats that matter: these are small, early-phase or single-center studies, with patient counts in the dozens to low hundreds. The Frontiers meta-analysis authors explicitly call for "larger, rigorously designed, and preferably multicenter randomized controlled trials" before conclusions can be considered reliable, citing inconsistent protocols and follow-up data. Mild short-term side effects like injection-site discomfort have occurred. No study has shown a cure, and long-term safety data remain limited.

Who Might Be a Candidate

• Someone with primary Sjögren's syndrome and significant dry eye or dry mouth that hasn't responded well to conventional treatments (artificial tears, saliva stimulants, anti-inflammatory eye drops)
• Someone specifically interested in participating in a registered clinical trial, where treatment is monitored and outcomes are tracked systematically
• Someone who understands this is not an FDA-approved or standard-of-care treatment, and who has discussed the experimental nature, costs, and risks with a rheumatologist or ophthalmologist
• Someone without contraindications to stem cell procedures, such as active infection or certain uncontrolled comorbidities (to be evaluated by a treating physician)
• Not a good fit: anyone seeking a guaranteed cure, anyone unable to access care through a legitimate research trial or accredited academic center, or anyone considering unregulated clinics offering unproven "stem cell infusions" without trial oversight

Bottom Line

The research on stem cell therapy for Sjögren's syndrome is genuinely encouraging in places — multiple small controlled trials have shown real improvements in dry eye symptoms, gland secretion, and disease activity, with reassuring short-term safety. That's meaningfully more than can be said for many experimental regenerative therapies. At the same time: there is no FDA-approved stem cell or disease-modifying cell therapy for Sjögren's syndrome, the evidence comes from a small number of early-phase trials rather than large confirmatory studies, and researchers themselves are calling for bigger trials before this becomes standard care. Anyone considering it should treat it as investigational, pursue it only through legitimate clinical trials or reputable academic centers, and talk candidly with their rheumatologist about realistic expectations, costs, and risks.